Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness

Phase 3 Withdrawn Romark Laboratories L.C.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective for treatment of mild COVID-19 illness. Adults and adolescent participants will be followed for approximately 28 days.

Timeline

Start: 2024-08
Primary completion: 2025-03
Completion: 2025-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Nitazoxanide	Other / unclassified	300 mg	Oral

Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness

Summary

Timeline

Drugs

Indications